CN EN

news

Shanghai, December 26, 2023 - The technical services of BioDuro-Sundia CMC department were once again recognized by its partners. Xu Wang, Director of Inna, Biguang Zhong, Executive Director, and Lili Xiong, Project Assistant, visited BioDuro-Sundia R&D Center in Shanghai to present the CMC department with the "Outstanding Partner Award". Dr. Jim Li, President of BioDuro-Sundia CMC Solutions (APAC), Hong Li, VP of Formulations, Hui Yu, VP of Analytics, and Dr. Lisheng Chen, Senior Director of Filing & Regulatory Affairs Office of BioDuro-Sundia, attended the ceremony.

Inna Pharma, an innovative pharmaceutical company, is committed to develop first-in-class small-molecule myeloid differentiation factor 88 (MyD88) inhibitors for the treatment of a wide range of serious major immune disorders. Advancing a 27-year line of research, Inna maintains demonstrated global specializing in both basic research and small-molecule inhibitor development. Over the years, the company has published 26 SCI papers unique to small molecule MyD88 inhibitors, attained 9 international and domestic patents, secured candidacy for 6 National Natural Science Foundation of China (NSFC) projects, and developed hundreds of active small molecule compounds. Inna has registered 1 IND application in the U.S. and China, with one particular pipeline currently “near-IND,” in addition to the company’s dozens of pipelines to be developed. At the beginning of this year, Inna announced the completion of Series A funding to the amount of 40 million RMB to be utilized for subsequent research registrations of MyD88.

Xu Wang, Director of Inna Pharma, stated, "the BioDuro-Sundia CMC team has worked together to provide us with a full range of professional and technical support. Efficient communication between departments has accelerated our progress." Dr. Jim Li, President of BioDuro-Sundia CMC Solutions (APAC), responded, "We are very grateful to receive Inna Pharma’s recognition and trust. Through strengthened collaboration, we advance Inna's R&D pipeline to reach new milestones. Dedicated to high standards and high quality, BioDuro-Sundia stands in full support of Inna Pharma’s promising new therapies."

BioDuro-Sundia provides global biopharmaceutical companies with a complete one-stop service platform for new drug R&D services and professional technical support. Complete CMC services offer global clients full integration from IND to NDA stage of pharmaceutical R&D and filing application. With extensive experience in R&D and NDA filing, familiarity with regulations and policies of China, the United States and Europe, efficient project management processes and optimized quality management systems, the CMC team has helped international clients complete more than 100+ IND projects, including more than 30+ dual submissions in both China and the United States.  Looking forward, BioDuro-Sundia will continue to invest in our CMC capabilities to extend and enhance partners’ new drug development programs with leading technical services.

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 9 global sites across 6 cities.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines. For more information, please visit www.bioduro-sundia.com.

Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
0.172260s
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all